Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates targeting cancers in areas of high unmet medical need, announced that it intends to offer and sell shares of its common stock in an underwritten public offering of 5 million shares of its common stock.
May 28, 2020
· 4 min read